NRNP 6634 Week 10 Prescribing Rationale Example

Course	NRNP 6634 Psychiatric Mental Health Advanced Practice Nursing Care of Adults and Older Adults
Week	Week 10
Paper type	Prescribing rationale
Length	About 800 words, 5 pages
Format	APA 7 student paper
School	Walden University
Program	MSN Psychiatric Mental Health Nurse Practitioner (PMHNP)
Updated	October 2026

Free sample paper for NRNP 6634 Week 10

Prescribing Rationale: Raising the Sertraline Dose Rather Than Switching to Mirtazapine, for a 72-Year-Old After a Setback

Student Name

College of Nursing, Walden University

NRNP 6634: Psychiatric Mental Health Advanced Practice Nursing Care of Adults and Older Adults

Instructor Name

Month Day, Year

What this page is doingThe title states the decision and the alternative in one line. The most frequent loss in this week is a rationale that explains a drug instead of defending a decision against a named alternative.

Prescribing Rationale: Raising the Sertraline Dose Rather Than Switching to Mirtazapine, for a 72-Year-Old After a Setback

The Decision

Increase sertraline from 50 mg to 100 mg daily, rather than switching to or adding mirtazapine. The patient is the composite woman of 72 carried through this course, in week 14 of treatment for recurrent major depression, with a setback after news of her daughter's move (PHQ-9 up from 9 to 15), new active suicidal ideation without intent or plan, and a safety plan in place.

The Alternative, Given Real Space

Mirtazapine, either as a switch or added at bedtime, deserved serious consideration. Her most troublesome symptoms are early waking and poor appetite with weight loss, and mirtazapine's sedating and appetite-increasing effects would target both directly. In head-to-head trials in a large network meta-analysis, mirtazapine was among the antidepressants more effective than others, although differences between drugs were modest and uncertain (Cipriani et al., 2018). A clinician choosing mirtazapine here would have a defensible case.

It was set aside for three reasons, given one at a time. First, sedation and falls: she lives alone, rises at night, and has knee osteoarthritis; a sedating medication at bedtime adds fall risk for a woman who would lie on the floor until someone found her. Second, the sertraline trial is incomplete: she has had 50 mg for 12 weeks and responded partially, improving from a PHQ-9 of 17 to 9 before the setback; a partial response at a low dose is a reason to increase the dose before abandoning the drug. Third, her own preference: asked, she said she wanted to "give the one that was working a fair chance" and did not want to feel "drugged at night."

Patient Factors That Decided It

Other conditions: hypothyroidism, controlled; hypertension; osteoarthritis. Other medicines: levothyroxine, amlodipine, and acetaminophen as needed; no anticoagulant or antiplatelet drug and no NSAID, so the bleeding risk that SSRIs add in combination with those drugs does not apply; diphenhydramine stopped in week 7. Organ function: creatinine normal; liver tests normal. Sodium: 136 mmol/L at week 3, after starting sertraline; the Beers Criteria flag SSRIs for caution in people her age on account of hyponatremia and SIADH (2023 American Geriatrics Society Beers Criteria Update Expert Panel, 2023), and mirtazapine carries the same caution, so the switch would not remove this risk. Prior response and intolerance: nausea early on at 50 mg, resolved within 2 weeks; nausea also led her to stop an antidepressant at 48, so the increase will be made gradually. What she said she would and would not take: she will take a higher dose of the current medicine; she would not take anything that makes her feel sedated at night.

Evidence Tied to This Decision

The network meta-analysis found that all 21 antidepressants studied were more effective than placebo, with modest and uncertain differences between them (Cipriani et al., 2018). That evidence does not make one drug the clear winner for her; it means the decision is made on her factors, and here they favor continuing the drug to which she partially responded, at a dose that has not yet been tried, over introducing a sedating one.

What the Decision Does Not Change

The dose increase is one part of her response to the setback, not the whole of it. Her safety plan was revised this week; the opioid tablets have been removed from her home; alcohol has stopped; visits are weekly; and psychotherapy continues, now focused on the coming loss of her daughter's daily nearness and on how she will keep her connection to her grandchildren across the distance. A medication change alone would not address the precipitant, and the rationale should not be read as if it did.

Her daughter was told, with her permission, that the dose is being raised and which side effects would warrant a call, and that the effect of the change is not expected for several weeks, so that the family does not read an unchanged mood in the first week as failure.

Monitoring and the Point of Review

Dose increase: 75 mg for 1 week, then 100 mg, to limit nausea. Sodium rechecked 2 weeks after reaching 100 mg, since older age, female sex, and low body weight all raise the risk of SSRI-associated hyponatremia (Jacob & Spinler, 2006). Falls, nausea, and sleep asked about at each visit. Suicidal ideation assessed at every visit, weekly for now, with 7-day dispensing continued while active ideation persists. Measure: PHQ-9 at each visit. Point of review: 6 weeks at 100 mg. If the PHQ-9 has not fallen below 10 by then, the next options are adding mirtazapine at a low dose at bedtime, if her fall risk can be addressed, or switching to another agent, and the decision will be revisited with her.

References

2023 American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372

Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7

Jacob, S., & Spinler, S. A. (2006). Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. The Annals of Pharmacotherapy, 40(9), 1618-1622. https://doi.org/10.1345/aph.1G293

What the NRNP 6634 Week 10 instructions ask for

Week 10 of NRNP 6634 often asks for a prescribing rationale for a specific medication decision. You state the decision, present the main alternative fairly, name the patient factors that decided it, tie evidence to the decision, say what the decision does not address and set monitoring with a review point. Faculty penalize rationales that recite mechanism and indications. Cite guidelines and trials in APA 7. Older adult safety should be considered explicitly. The alternative should take a meaningful share of the paper. Doses may be named in this assignment, unlike earlier weeks. NRNP 6634 faculty want the decision in the first sentence and the alternative described with its strongest advantages. Name each patient factor that tipped the choice. State the review date and what will be measured then.

How the NRNP 6634 Week 10 example is put together

The rationale opens on its decision and uses every later paragraph to justify it. The main competing option comes next, which is the move most rationales skip, and the reasons it was set aside are given one at a time. Patient factors follow: other conditions carried, other medicines already in use and how they interact, organ function in an older adult, prior response and prior intolerance, what the adult said they would and would not take, and what is obtainable where they live. Evidence appears after that, cited to current primary literature or a named guideline rather than to a course text. Monitoring follows with intervals. A closing paragraph states what response would confirm the choice and what would send the writer back to the alternative.

Where the marks sit in the NRNP 6634 Week 10 rubric

Rationales lose marks when they explain a drug instead of defending a decision. A document reciting mechanism and indications collects background credit and leaves the reasoning row empty, because nothing in it is specific to the person. Omitting the alternative costs the comparison point outright, and it is the most frequent single loss in this week. Generic patient factors cost the same way, since a rationale that would fit any adult of that age has not used the case it was given. Older sources cost currency where a section sets a date range, and course texts cited in place of primary literature cost the evidence row. Documents stopping at the decision, with no monitoring and no trigger for revisiting it, lose the follow-through criterion most rubrics carry.

Common NRNP 6634 Week 10 mistakes, and how to avoid them

Rationales lose marks when they explain how a drug works rather than why this choice beats the alternative. Defend the decision. Another common gap is giving the alternative a sentence. Give it real space with its advantages. Writers also cite evidence about the drug class in general instead of the decision. Tie evidence to dose increase versus switch. Avoid ignoring fall risk with sedating drugs in older adults. Name what the decision leaves unchanged, such as therapy. Set a review point. Close with the side effects she should report. Writers also forget sodium checks in older adults on SSRIs, since hyponatremia can follow a dose rise. Plan one. Another frequent slip is ignoring drug interactions with her other medications. Review them.

Get a NRNP 6634 Week 10 example written to your instructions

Send the Week 10 prompt with the case and the rubric your section supplied, and the desk writes the rationale as a finished document, decision stated, alternative argued, evidence attached and review set. The first custom sample is free and returns inside 24-48 hours. It is coursework written to your prompt, never advice about a patient.

More NRNP 6634 papers and PMHNP samples

NRNP 6634 Week 10 questions, answered

Will the sample name a drug?

The finished document names the agent chosen and the one it was weighed against, because the assignment cannot be answered otherwise. This page names neither, and nothing the desk writes is advice about any real person's care. The rationale is coursework, defended against sources, and that framing is stated openly at the top of the file itself.

How much of the document is about the alternative?

Roughly a third of it in the example, which surprises writers who expected a closing note. The comparison is the assignment, and a rejected option handled in one line gives a marker no way to see judgment at work. Each reason for setting it aside is written as its own point, tied to a factor already established in the case.

What counts as acceptable evidence here?

Current primary literature and named clinical guidelines, cited at the place where the decision they support is made. Course textbooks and drug reference summaries tend to sit outside what evidence rows credit, even when the content is correct, because they are not the level of source the criterion describes. The example cites at the point of use rather than assembling a list at the end.

Where can I find a free NRNP 6634 Week 10 sample paper?

The sertraline dose rationale is reproduced here with the decision, the mirtazapine alternative, the deciding patient factors, the evidence and the review point.

Why raise sertraline rather than switch in NRNP 6634 Week 10?

She had a partial response at a low dose, and an increase keeps that gain while avoiding new sedation and fall risk. The example sets a review in four to six weeks.